Related Experiment Video
Updated: Aug 12, 2026
09:27
Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
Mathematical modelling of antifungal action
1Université de la Méditerranée, Faculté de Pharmacie, Pharmacochimie Antiparasitaire, Organique et Naturelle, EA 864, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France.
Mycoses
|December 11, 2002
Summary
This study introduces a mathematical model for antifungal drug efficacy, showing yeast growth inhibition follows exponential and hyperbolic functions. This model predicts drug concentrations and identifies yeast-antifungal affinity.
Area of Science:
- Microbiology
- Pharmacology
- Mathematical Biology
Background:
- Antifungal drug efficacy is crucial for treating yeast infections.
- Understanding drug-host-pathogen interactions requires quantitative models.
- Current methods for determining drug effectiveness have limitations.
Purpose of the Study:
- To develop a simplified mathematical model for yeast growth inhibition by antifungal drugs.
- To characterize inhibition kinetics using exponential and hyperbolic functions.
- To predict drug efficacy and synergistic potential.
Main Methods:
- Developed a simplified mathematical model for yeast growth inhibition.
- Modeled inhibition rate using hyperbolic functions.
- Calculated affinity constant (Kaff) and minimum inhibitory concentration (MIC80).
- Simulated theoretical inhibition levels at high drug concentrations.
Main Results:
- Yeast growth inhibition by antifungal drugs follows an exponential function.
- Inhibition rate is described by a hyperbolic function.
- Calculated Kaff is specific to yeast strain and antifungal drug.
- Model predicts inhibition levels unattainable experimentally.
Conclusions:
- The mathematical model accurately describes yeast growth inhibition kinetics.
- The model provides a method to determine key parameters like Kaff and MIC80.
- This approach can predict antifungal synergy and optimize treatment strategies.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...